Now published: Proceedings of The GRAPPA 2025 Annual Meeting
Explore the latest insights on psoriasis and psoriatic arthritis, including AI, imaging, and innovative therapies.
@jrheumatol.bsky.social
@jrheumatol.bsky.socialNow published: Proceedings of The GRAPPA 2025 Annual Meeting
Explore the latest insights on psoriasis and psoriatic arthritis, including AI, imaging, and innovative therapies.
@mithurheum.bsky.social🆕 Visual Abstract with Healio 🎨
#Deucravacitinib in Psoriatic Arthritis: POETYK PsA-2
🎲 Phase 3 RCT of Deucravacitinib vs PBO
💊 Deucravacitinib = oral, selective TYK2 inhibitor
🥇 1st FDA-approved TYK2i for PsA
Healio Article 🔗: vist.ly/5hps8
@jrheumatol.bsky.socialResearch Article
Overall and Sex-Specific Predictors of Secukinumab Effectiveness in European Patients With Psoriatic Arthritis: Results From the EuroSpA Collaboration
@iprolepsis.bsky.social@iprolepsis.bsky.social has published an updated report on the state of the art and relevant datasets for psoriatic arthritis, covering symptoms, flare-related factors, monitoring approaches and predictive modelling.
@psahq.bsky.socialSeptember is reset time for many of us, including researchers. So what do we, as people living with PsA, still need and want to know?
September musings in a new Substack blog post - please check it out and share.
The link is on my bio page 🔗